All In Biotech

NDA 208552 · Mayne Pharma

Rhofade

Oxymetazoline Hydrochloride · Topical

Novel

Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jan 18, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

655

76 Phase 3, 27 recruiting

FAERS reports

910

410 serious, 26 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 13, 2026.

Oxymetazoline Hydrochloride Cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. Oxymetazoline Hydrochloride Cream is an alpha 1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. ( 1 )

Mechanism: Oxymetazoline is an alpha 1A adrenoceptor agonist. Oxymetazoline acts as a vasoconstrictor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 18, 2017 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
1 products under this application
  • RHOFADE · OXYMETAZOLINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxymetazoline" as an intervention, any sponsor and status, largest first.

All 655 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site erythema84
  • drug ineffective64
  • nausea55
  • rosacea54
  • fatigue53
  • application site pain49
  • erythema48
  • pain47
  • pruritus45
  • diarrhoea44
  • condition aggravated39
  • headache39

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
20061
20073
20084
20096
20101
20113
20127
201311
20149
201511
201623
201753
201885
201979
202041
202158
2022122
2023132
202491
2025106
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rhofade (Oxymetazoline HCl)

2024 spending

$928K

Beneficiaries

1,269

1,474 claims

Per beneficiary

$731

$19.99 per unit

View as table
YearSpending
2020$0
2021$1,748,180
2022$2,655,700
2023$2,516,617
2024$927,789

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 149 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.